Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01229501 · ClinicalTrials.gov registry record

Fat Biology, Sleep Disorders, and Cardiovascular Disease

A clinical trial of Cardiovascular Disease and Sleep Disordered Breathing, sponsored by Mayo Clinic.

Completed
Registry status
14
Enrollment target
1
Study location

NCT01229501 is a study of Cardiovascular Disease and Sleep Disordered Breathing that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01229501, a study of Cardiovascular Disease and Sleep Disordered Breathing, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

Endothelial dysfunction, or abnormal functioning of the lining of blood vessels, appears to be a key process in the development of cardiovascular disease. Endothelial dysfunction appears to be caused by both sleep disordered breathing and obesity. As endothelial dysfunction is among the first clinical marker that predicts future cardiovascular events, understanding molecular mechanisms leading to impairment of endothelial function is very important. Endothelial function requires the proper functioning of endothelial nitric oxide synthase (eNOS). eNOS activity is tightly regulated by caveolin-1, a protein important in the formation of cellular structures called caveolae. Low levels of caveolin-1 facilitate optimal nitric oxide synthesis in endothelial cells as caveolin-1 helps to spatially organize eNOS in close proximity to signaling proteins that are important for eNOS activation. In certain diseases however, the balance of caveolin-1 and eNOS can be disrupted resulting in impaired nitric oxide synthesis and leading to endothelial dysfunction. The investigators therefore seek to characterize levels of caveolin-1, and correlate this with the presence or absence of sleep disordered breathing, obesity, and cardiovascular disease. The current IRB protocol covers the performance of fat biopsies on subjects who have recently completed a sleep study either in the Center for Sleep Medicine or in our sleep laboratory and were found to have sleep disordered breathing or no sleep disordered breathing, subject with sleep disordered breathing who have been treated successfully with continuous positive airway pressure for 3-6 months, and subjects undergoing other studies in our lab who are obese or non-obese and subjects who have known cardiovascular disease and subjects without known cardiovascular disease.

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2010-03
Est. Completion 2016-02

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT01229501

The ClinicalTrials.gov registry entry for NCT01229501 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01229501 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01229501 about?

NCT01229501 is a clinical study titled "Fat Biology, Sleep Disorders, and Cardiovascular Disease". Endothelial dysfunction, or abnormal functioning of the lining of blood vessels, appears to be a key process in the development of cardiovascular disease. Endothelial dysfunction appears to be caused by both sleep disordered breathing and obesity. As endothelial dysfunction is among the first clinic...

What is the current status of trial NCT01229501?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2010-03. Estimated completion is 2016-02.

What conditions does trial NCT01229501 study?

This clinical trial studies the following conditions: Cardiovascular Disease, Sleep Disordered Breathing.

Who is sponsoring clinical trial NCT01229501?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01229501 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.